IL217383A - Mesenchymal progenitor cell differentiation - Google Patents

Mesenchymal progenitor cell differentiation

Info

Publication number
IL217383A
IL217383A IL217383A IL21738312A IL217383A IL 217383 A IL217383 A IL 217383A IL 217383 A IL217383 A IL 217383A IL 21738312 A IL21738312 A IL 21738312A IL 217383 A IL217383 A IL 217383A
Authority
IL
Israel
Prior art keywords
stem cell
mesenchymal stem
cell differentiation
differentiation
mesenchymal
Prior art date
Application number
IL217383A
Other languages
English (en)
Hebrew (he)
Other versions
IL217383A0 (en
Original Assignee
Scripps Research Inst
Novartis Ag
Novartis Int Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL217383(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Novartis Ag, Novartis Int Pharmaceutical Ltd filed Critical Scripps Research Inst
Publication of IL217383A0 publication Critical patent/IL217383A0/en
Publication of IL217383A publication Critical patent/IL217383A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/515Angiogenesic factors; Angiogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1891Angiogenesic factors; Angiogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL217383A 2009-07-14 2012-01-05 Mesenchymal progenitor cell differentiation IL217383A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
PCT/US2010/041850 WO2011008773A2 (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Publications (2)

Publication Number Publication Date
IL217383A0 IL217383A0 (en) 2012-02-29
IL217383A true IL217383A (en) 2016-08-31

Family

ID=43450138

Family Applications (2)

Application Number Title Priority Date Filing Date
IL217383A IL217383A (en) 2009-07-14 2012-01-05 Mesenchymal progenitor cell differentiation
IL247310A IL247310B (en) 2009-07-14 2016-08-17 Mesenchymal stem cell differentiation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL247310A IL247310B (en) 2009-07-14 2016-08-17 Mesenchymal stem cell differentiation

Country Status (30)

Country Link
US (4) US9139633B2 (Direct)
EP (1) EP2453921B1 (Direct)
JP (1) JP5602850B2 (Direct)
KR (3) KR20160015403A (Direct)
CN (2) CN102625830B (Direct)
AU (1) AU2010273570B2 (Direct)
BR (1) BR112012000914B8 (Direct)
CA (1) CA2767826C (Direct)
CL (1) CL2012000091A1 (Direct)
CO (1) CO6491059A2 (Direct)
CR (1) CR20120024A (Direct)
CU (1) CU24042B1 (Direct)
EA (1) EA023073B1 (Direct)
EC (1) ECSP12011604A (Direct)
ES (1) ES2541217T3 (Direct)
GT (1) GT201200011A (Direct)
IL (2) IL217383A (Direct)
IN (1) IN2012DN00572A (Direct)
MA (1) MA33423B1 (Direct)
MX (1) MX2012000707A (Direct)
MY (1) MY160951A (Direct)
NZ (1) NZ597306A (Direct)
PE (2) PE20160507A1 (Direct)
PL (1) PL2453921T3 (Direct)
PT (1) PT2453921E (Direct)
SG (1) SG177318A1 (Direct)
TN (1) TN2011000655A1 (Direct)
UA (1) UA104031C2 (Direct)
WO (1) WO2011008773A2 (Direct)
ZA (1) ZA201200078B (Direct)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP2779649A4 (en) 2011-11-08 2016-01-06 Korea Electronics Telecomm METHOD AND DEVICE FOR THE JOINT USE OF A CANDIDATE LIST
WO2014004465A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
ES2900815T3 (es) 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
RS66122B1 (sr) 2014-05-13 2024-11-29 Novartis Ag Jedinjenja i kompozicije za indukciju hondrogeneze
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
IL266361B2 (en) * 2016-11-14 2024-02-01 Novartis Ag Methods and preparations for the treatment of cartilage damage and arthritis
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣3多肽之持續遞送
US12365692B2 (en) 2018-12-06 2025-07-22 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015735B (zh) 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替(上海)生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) * 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 97個のヒト分泌タンパク質
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
AU768694B2 (en) 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
ES2338492T3 (es) * 2000-10-16 2010-05-07 Genentech, Inc. Polipeptidos wips y aplicaciones terapeuticas de los mismos.
US20030120056A1 (en) * 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
JP5105696B2 (ja) * 2001-11-16 2012-12-26 ジェネンテック, インコーポレイテッド アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法
RS20050202A (sr) * 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Vodo-rastvorni polimerni alkanali
AU2004219820B2 (en) * 2003-03-10 2008-06-12 Japan Science And Technology Agency Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
EP1771196B1 (en) * 2004-06-21 2012-03-28 The Cleveland Clinic Foundation Ccr ligands for stem cell homing
WO2006098887A2 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7807464B2 (en) 2005-05-24 2010-10-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
JP2010525836A (ja) * 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のexvivo増殖
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular

Also Published As

Publication number Publication date
KR20180000337A (ko) 2018-01-02
EP2453921A4 (en) 2012-12-19
IN2012DN00572A (Direct) 2015-06-12
SG177318A1 (en) 2012-03-29
US20190000922A1 (en) 2019-01-03
PL2453921T3 (pl) 2015-11-30
US10555990B2 (en) 2020-02-11
EA201200118A1 (ru) 2012-09-28
US9139633B2 (en) 2015-09-22
US20160213748A1 (en) 2016-07-28
MA33423B1 (fr) 2012-07-03
KR20160015403A (ko) 2016-02-12
KR20120029472A (ko) 2012-03-26
WO2011008773A3 (en) 2011-08-25
CN102625830A (zh) 2012-08-01
CA2767826A1 (en) 2011-01-20
EA023073B1 (ru) 2016-04-29
ES2541217T3 (es) 2015-07-16
TN2011000655A1 (en) 2013-05-24
PT2453921E (pt) 2015-09-25
IL247310B (en) 2018-04-30
CU20120007A7 (es) 2013-02-26
BR112012000914B1 (pt) 2021-04-06
US20200108122A1 (en) 2020-04-09
CN105601728A (zh) 2016-05-25
WO2011008773A2 (en) 2011-01-20
BR112012000914A2 (pt) 2017-08-08
NZ597306A (en) 2014-03-28
CA2767826C (en) 2015-11-24
PE20160507A1 (es) 2016-05-20
ZA201200078B (en) 2013-01-30
KR101590834B1 (ko) 2016-02-12
CU24042B1 (es) 2014-11-27
JP2012533549A (ja) 2012-12-27
GT201200011A (es) 2013-12-10
JP5602850B2 (ja) 2014-10-08
EP2453921A2 (en) 2012-05-23
MY160951A (en) 2017-03-31
CN105601728B (zh) 2020-01-10
CO6491059A2 (es) 2012-07-31
AU2010273570B2 (en) 2014-07-03
EP2453921B1 (en) 2015-05-27
CR20120024A (es) 2012-06-11
BR112012000914B8 (pt) 2021-05-25
US11241482B2 (en) 2022-02-08
AU2010273570A1 (en) 2012-02-02
UA104031C2 (uk) 2013-12-25
MX2012000707A (es) 2012-03-21
US20120177644A1 (en) 2012-07-12
CL2012000091A1 (es) 2012-10-26
US10064918B2 (en) 2018-09-04
ECSP12011604A (es) 2012-06-29
BR112012000914A8 (pt) 2017-12-19
HK1164169A1 (en) 2012-09-21
CN102625830B (zh) 2016-03-02
PE20120570A1 (es) 2012-05-19
IL217383A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
IL247310B (en) Mesenchymal stem cell differentiation
SG10201500674YA (en) Pluripotent stem cells
SG10201403202XA (en) Pre-natal mesenchymal stem cells
PL2254586T3 (pl) Cząstki mezenchymalnych komórek macierzystych
IL228818A0 (en) Stem cell cultures
ZA201100758B (en) Differentiation of pluripotent stem cells
GB0908613D0 (en) T Cell Reseptors
IL216624A0 (en) Fucosylation-deficient cells
GB0814249D0 (en) Uses of mesenchymal stem cells
IL214818A0 (en) Differentiation of pluripotent cells
SI2639296T1 (sl) Suspenzija matičnih celic
GB0914195D0 (en) Vessel for culturing cells
GB0920775D0 (en) Cells
EP2294182A4 (en) CULTS OF MULTIPOTENT STEM CELLS
GB0919773D0 (en) Induced pluripotent stem cell
GB0918471D0 (en) Stem cells
GB0901069D0 (en) Stem cell culture methods
GB0916476D0 (en) Stem cell culture methods
GB0915268D0 (en) Cell culture
GB0922428D0 (en) Cell culture
AU2009901351A0 (en) Stem cell maintenance
GB0920035D0 (en) Cell
GB0901675D0 (en) Cells
GB0908223D0 (en) Cells
HUE052153T2 (hu) Fukoziláció-deficiens sejtek

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed